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Abstract 
Treatment effects vary across different patients and estimation of this variability is 
important for clinical decisions. The aim is to develop a model to estimate the benefit of 
alternative treatment options for individual patients. Hence, we developed a two-stage 
prediction model for heterogeneous treatment effects, by combining prognosis research and 
network meta-analysis methods when individual patient data is available.  In a first stage, we 
develop a prognostic model and we predict the baseline risk of the outcome. In the second 
stage, we use this baseline risk score from the first stage as a single prognostic factor and 
effect modifier in a network meta-regression model. We apply the approach to a network 
meta-analysis of three randomized clinical trials comparing the relapse rate in Natalizumab, 
Glatiramer Acetate and Dimethyl Fumarate including 3590 patients diagnosed with relapsing-
remitting multiple sclerosis. We find that the baseline risk score modifies the relative and 
absolute treatment effects. Several patient characteristics such as age and disability status 
impact on the baseline risk of relapse, and this in turn moderates the benefit that may be 
expected for each of the treatments.  For high-risk patients, the treatment that minimizes the 
risk to relapse in two years is Natalizumab, whereas for low-risk patients Dimethyl Fumarate 
Fumarate might be a better option. Our approach can be easily extended to all outcomes of 
interest and has the potential to inform a personalised treatment approach.   
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1 Introduction 
Personalized predictions are important for clinical decision-making. The question ‘Which 
treatment is best?’ can have two very different meanings: ‘Which treatment is best on 
average?’ or ‘Which treatment is best for a specific patient?’  Patients often experience 
different outcomes under the same treatment. One patient may benefit more by a treatment 
from which another patient may benefit less. Thus, it is essential to identify via risk 
modelling approach those patient characteristics that influence treatment effects in order to 
choose the best option for a given patient effects. Prediction models aim to identify and 
estimate the impact of patient, intervention and setting characteristics on future health 
outcomes. The baseline risk of patients is often a determinant of heterogeneous treatment 
effects (1). 
The baseline risk expresses the probability of developing the studied outcome prior to 
any intervention. Models that link the baseline risk to patient characteristics have been 
referred to as prognostic models or risk models. A prognostic and a prediction model can be 
combined in a risk modelling approach that uses the baseline risk of patients to predict 
heterogeneous treatment effects, typically within a randomised clinical trial (RCT) (1), (2), 
(3), (4). The first step is to develop a multivariable prognostic model that predicts the 
probability of developing the studied outcome blinded to the treatment - this can be done 
using observational or RCT data. We will term this baseline risk from now on, and a 
transformation of the risk will be termed baseline risk score. Several established methods 
exist for developing a prognostic model (5), (6), (7), (8). At a second step, relative treatment 
effects within RCTs can be estimated as a function of the baseline risk score using a 
prediction model (9). This methodology allows for heterogeneity in baseline risk, in the 
relative treatment effects and consequently in the absolute treatment effects too. The risk 
modelling approach has recently gained ground for personalized predictions under a 
treatment of choice (1), (3).  
Multiple sclerosis (MS) is an autoimmune disease of the central nervous system with 
several subtypes. The most common subtype is relapsing-remitting Multiple Sclerosis 
(RRMS)(10). Patients with RRMS present with intense symptoms (relapses) followed by 
periods without symptoms (remission) (11). Several treatments are available (12) with 
heterogeneous patient responses and each treatment has a very different safety profile.  
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The evidence about  drugs for relapsing-remitting MS has been summarized using 
network meta-analysis (13), (14). These networks typically synthesize published aggregated 
data and therefore their ability to explore individual patient characteristics and to examine 
how treatment effects (relative or absolute) vary across different patients is limited. More 
efficient analyses use individual patient data (IPD), which are considered the gold standard in 
evidence synthesis and are necessary for estimating heterogeneous treatment effects and 
inform models that can make personalized predictions of expected outcomes (15), (16). 
Patient and setting characteristics can be included in network meta-regression models to 
make predictions for different treatments and subgroups of patients. However, this approach 
presents several computational and practical difficulties when many predictors are to be 
included in the model. Model selection techniques and shrinkage methods have not yet been 
developed for IPD meta-regression models; with many predictors, issues of low power and 
optimism render the approach challenging.  
2 Methods 
In this paper, we aim to define a methodological framework that allows personalized 
predictions for the most likely outcome under several treatment options. To achieve this we 
adapt the risk modelling approach for the context of meta-analysis. We combine ideas from 
prognostic modelling to estimate the baseline risk score and include this score in an IPD 
network meta-regression (NMR). We apply this method in a set of trials comparing three 
drugs and placebo in patients with RRMS. We also examine how different prognostic models 
to estimate the baseline risk score influence the results of the predictive model and the 
estimated absolute and relative treatment effects (6), (17). We present results primarily for 
the absolute treatment effects, as these will vary across patient groups, even if heterogeneity 
is present only in the baseline risk but not in the relative treatment effects. We first describe 
the general framework, applicable to any type of data and network (section 2.1).  In section 
2.2, we detail the implementation of the framework in the context of drugs for RRMS.  
2.1 General description of the model 
We built a two-stage model where we first developed the baseline risk score and then 
estimated the probabilities of the post-treatment outcome as a function of the baseline risk 
score. The baseline risk score is determined using established methods (6), (17), (18). The 
second stage uses an IPD NMR model that includes the baseline risk score and its interaction 
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with the treatment as predictors of the outcome.  Our approach assumes that the set of 
selected variables captures in the first stage captures adequately both prognosis and effect 
modification. We describe the approach for a dichotomous outcome of interest, although 
continuous outcomes can also be modelled with minor modifications.  
2.1.1 Notation 
Let 𝑌𝑌𝑖𝑖𝑖𝑖  denote the dichotomous outcome for individual 𝑖𝑖 where 𝑖𝑖=1, 2, …, 𝑛𝑛  in the 𝑗𝑗 study 
out of 𝑛𝑛𝑛𝑛 trials. 𝑃𝑃𝑃𝑃𝑖𝑖𝑖𝑖𝑖𝑖 is the 𝑘𝑘 prognostic factor and 𝑛𝑛𝑛𝑛 is the total number of prognostic 
factors. An individual can develop the outcome (𝑌𝑌𝑖𝑖𝑖𝑖 = 1)  or not (𝑌𝑌𝑖𝑖𝑖𝑖 = 0)  according to their 
risk at baseline, which is a function of the prognostic factors and we denote it with 𝑅𝑅𝑖𝑖𝑖𝑖 . 
Assume we have a set of treatments ℋ each denoted by 𝑡𝑡 ∈ ℋ where 𝑡𝑡 = 1, 2, … ,𝑇𝑇. The 
probability  𝑛𝑛𝑖𝑖𝑖𝑖𝑖𝑖 is the probability of the outcome for the 𝑖𝑖 individual in 𝑗𝑗 study under 
treatment 𝑡𝑡 and depends on treatment, baseline risk score and the interaction between the risk 
score and the treatment. 
2.1.2 Stage 1: Developing a baseline risk score model 
We developed a risk model using two different methods for a dichotomous outcome: a 
risk model selected via the LASSO method and a pre-specified risk model. Observational or 
RCT data may be used for this purpose; in the application of the model only placebo-
controlled RCTs are available.  According to previous recommendations, developing a 
baseline risk score using RCTs, should use not only the placebo arms, but the entire sample 
blinded to the treatment  (2).  The logistic regression model is 
𝑌𝑌𝑖𝑖𝑖𝑖~𝐵𝐵𝐵𝐵𝐵𝐵𝑛𝑛𝐵𝐵𝐵𝐵𝐵𝐵𝐵𝐵𝑖𝑖(𝑅𝑅𝑖𝑖𝑖𝑖) 
𝐵𝐵𝐵𝐵𝑙𝑙𝑖𝑖𝑡𝑡�𝑅𝑅𝑖𝑖𝑖𝑖� = 𝑏𝑏0𝑖𝑖 + ∑ 𝑏𝑏𝑖𝑖𝑖𝑖 × 𝑃𝑃𝑃𝑃𝑖𝑖𝑖𝑖𝑖𝑖𝑛𝑛𝑛𝑛𝑖𝑖=1   (1) 
The regression coefficients and intercept can be independent, exchangeable 
(𝑏𝑏0𝑖𝑖~𝑁𝑁(𝛽𝛽0,𝜎𝜎𝛣𝛣02 ), 𝑏𝑏𝑖𝑖𝑖𝑖~𝑁𝑁(𝛽𝛽𝑖𝑖,𝜎𝜎𝛣𝛣𝑘𝑘2 )) or common (𝑏𝑏0𝑖𝑖 = 𝛽𝛽0, 𝑏𝑏𝑖𝑖𝑖𝑖 = 𝛽𝛽𝑖𝑖) across studies. For 
model selection, methods that include some form of penalization are preferred to stepwise 
selection  (5), (6), (17). The latter include LASSO (Least Absolute Shrinkage and Selection 
Operator). However, including a set of predictors informed by prior knowledge (either in the 
form of expert opinion or previously identified variables in prognostic studies) has conceptual 
and computational advantages (17), (18), (19). The estimated  effects of the selected 
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covariates also needs some form of penalisation to avoid extreme predictions (6), (5).  In the 
application, we discuss several possibilities (see section 2.2.2).  
Validation is essential for evaluating the performance of a prognostic model (7). As 
external data were not available, we performed internal validation only. To evaluate the 
discriminative performance and the calibration ability we estimated the c-statistic and the 
calibration slope of the developed risk models. To account for optimism, which is particularly 
important when comparing various models, we used bootstrap (6). We produced 500 
bootstraps samples and reran the model selection process and estimation in each sample. 
Then, we assessed the performance of each bootstrap-based model in the original sample 
(20), (21).   
2.1.3 Stage 2: IPD Network meta-regression model 
In the second stage we use the logit of the baseline risk as a covariate in an IPD NMR 
model (22). Each study 𝑗𝑗 has an arbitrarily chosen baseline treatment ℎ𝑖𝑖  ∈ ℋ  and then each 
individual 𝑖𝑖 is randomized to any treatment 𝑡𝑡 ∈ ℋ. The meta-regression equation in study 𝑗𝑗 
with a baseline treatment 𝑏𝑏𝑖𝑖 will be: 
𝑌𝑌𝑖𝑖𝑖𝑖~𝐵𝐵𝐵𝐵𝐵𝐵𝑛𝑛𝐵𝐵𝐵𝐵𝐵𝐵𝐵𝐵𝑖𝑖(𝑛𝑛𝑖𝑖𝑖𝑖𝑖𝑖) 
𝐵𝐵𝐵𝐵𝑙𝑙𝑖𝑖𝑡𝑡�𝑛𝑛𝑖𝑖𝑖𝑖𝑖𝑖�
= � 𝐵𝐵𝑖𝑖 + 𝑙𝑙0𝑖𝑖 × �𝐵𝐵𝐵𝐵𝑙𝑙𝑖𝑖𝑡𝑡�𝑅𝑅𝑖𝑖𝑗𝑗� − 𝐵𝐵𝐵𝐵𝑙𝑙𝑖𝑖𝑡𝑡(𝑅𝑅𝑖𝑖𝑗𝑗)��������������𝑗𝑗�  𝑖𝑖𝑖𝑖  𝑡𝑡 = ℎ𝑗𝑗
𝐵𝐵𝑖𝑖 + 𝑑𝑑𝑖𝑖ℎ𝑗𝑗𝑖𝑖 + 𝑙𝑙0𝑖𝑖 × �𝐵𝐵𝐵𝐵𝑙𝑙𝑖𝑖𝑡𝑡�𝑅𝑅𝑖𝑖𝑗𝑗� − 𝐵𝐵𝐵𝐵𝑙𝑙𝑖𝑖𝑡𝑡(𝑅𝑅𝑖𝑖𝑗𝑗)��������������𝑗𝑗 � + 𝑙𝑙𝑖𝑖ℎ𝑗𝑗𝑖𝑖 × �𝐵𝐵𝐵𝐵𝑙𝑙𝑖𝑖𝑡𝑡�𝑅𝑅𝑖𝑖𝑗𝑗� − 𝐵𝐵𝐵𝐵𝑙𝑙𝑖𝑖𝑡𝑡(𝑅𝑅𝑖𝑖𝑗𝑗)��������������𝑗𝑗� ,  𝑖𝑖𝑖𝑖 𝑡𝑡 ≠ ℎ𝑗𝑗  
(2) 
where 𝐵𝐵𝐵𝐵𝑙𝑙𝑙𝑙𝑡𝑡(𝑅𝑅𝚤𝚤𝚤𝚤)�������������𝑖𝑖 is the average of logit-risk in all individuals in study 𝑗𝑗. The relative 
treatments effects are the log-odds ratios 𝑑𝑑𝑖𝑖ℎ𝑗𝑗𝑖𝑖  and can be random (𝑑𝑑𝑖𝑖ℎ𝑗𝑗𝑖𝑖~𝑁𝑁(𝐷𝐷ℎ𝑗𝑗𝑡𝑡,𝜎𝜎𝐷𝐷2 )) or fixed 
(𝑑𝑑𝑖𝑖ℎ𝑗𝑗𝑖𝑖 = 𝐷𝐷ℎ𝑗𝑗𝑡𝑡) across studies. Then, assuming consistency we set the constraint 𝐷𝐷ℎ𝑗𝑗𝑖𝑖 = 𝛿𝛿𝑖𝑖 −
𝛿𝛿ℎ𝑗𝑗 and  𝛿𝛿𝑟𝑟𝑟𝑟𝑟𝑟 = 0 where 𝛿𝛿𝑖𝑖 is the summary estimate for log-odds ratios for treatment t versus 
the overall reference treatment (𝐵𝐵𝐵𝐵𝑖𝑖). Parameter 𝑙𝑙0𝑖𝑖 is the coefficient of the risk score (as a 
prognostic factor) and can be independent, exchangeable (𝑙𝑙0𝑖𝑖~𝑁𝑁(𝛾𝛾0,𝜎𝜎𝛾𝛾02 ), or fixed (𝑙𝑙0𝑖𝑖 =
𝛾𝛾0). Similarly,  𝑙𝑙𝑖𝑖ℎ𝑗𝑗𝑖𝑖 refers to the treatment effect modification of the risk score, for treatment 
𝑡𝑡 versus study’s baseline treatment ℎ𝑖𝑖 , and can be random 
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(𝑙𝑙𝑖𝑖ℎ𝑗𝑗𝑖𝑖~𝑁𝑁(𝐺𝐺ℎ𝑗𝑗𝑡𝑡,𝜎𝜎𝐺𝐺2 )) or fixed (𝑙𝑙𝑖𝑖ℎ𝑗𝑗𝑖𝑖 = 𝐺𝐺ℎ𝑗𝑗𝑡𝑡), where 𝐺𝐺ℎ𝑗𝑗𝑡𝑡 = 𝛾𝛾𝑡𝑡 − 𝛾𝛾ℎ𝑗𝑗 and 𝛾𝛾𝑟𝑟𝑟𝑟𝑟𝑟 = 0. Finally,  
exp(𝛾𝛾𝑖𝑖) is the ratio of two ORs of treatment 𝑡𝑡 versus the reference: the OR of a group of 
people with baseline score 𝑥𝑥 over the OR in a group of people with baseline risk score 𝑥𝑥 − 1.    
Assume that there is an overall reference treatment (like placebo) for which predictions 
are less important. Then, consider a patient at the mean (logit) baseline population risk, 𝑅𝑅� 
who is also under this overall reference treatment. This logit-probability of the outcome is 
denoted with, say, 𝛼𝛼. To make predictions for a new patient with predicted risk 𝐵𝐵𝐵𝐵𝑙𝑙𝑙𝑙𝑡𝑡(𝑅𝑅𝚤𝚤)�  and 
in treatment 𝑡𝑡, we use the equation: 
𝐵𝐵𝐵𝐵𝑙𝑙𝑖𝑖𝑡𝑡(𝑛𝑛𝑖𝑖) = 𝑎𝑎 + 𝛿𝛿𝑖𝑖 + 𝛾𝛾0 × �𝐵𝐵𝐵𝐵𝑙𝑙𝑖𝑖𝑡𝑡(𝑅𝑅𝑖𝑖)� −𝐵𝐵𝐵𝐵𝑙𝑙𝑖𝑖𝑡𝑡(𝑅𝑅)������������� + 𝛾𝛾𝑖𝑖 × �𝐵𝐵𝐵𝐵𝑙𝑙𝑖𝑖𝑡𝑡(𝑅𝑅𝑖𝑖)� −𝐵𝐵𝐵𝐵𝑙𝑙𝑖𝑖𝑡𝑡(𝑅𝑅)�������������,   (3) 
Estimation of 𝑎𝑎 and  𝐵𝐵𝐵𝐵𝑙𝑙𝑙𝑙𝑡𝑡(𝑅𝑅)����������� depends on the context within which we plan to make 
prediction. Registry data or observational studies can be used to extrapolate to a specific 
context, or the same RCT data as previously can be used. For example, 𝐵𝐵𝐵𝐵𝑙𝑙𝑙𝑙𝑡𝑡(𝑅𝑅)����������� can be 
estimated as the mean of 𝐵𝐵𝐵𝐵𝑙𝑙𝑖𝑖𝑡𝑡(𝑅𝑅𝑖𝑖𝑖𝑖) across all individuals and studies. Similarly, 𝑎𝑎 can be 
estimated from the synthesis of all relevant arms (externally to the model) or by estimating 
the outcome in those patients in the overall reference treatment with baseline risk close to 
overall mean.   
2.2 Application: predicting relapses in multiple sclerosis under different treatments 
2.2.1 Data description  
We analysed IPD from three phase III randomized clinical trials (23), (24), (25) on patients 
diagnosed with relapsing-remitting MS.  Altogether, the trials included 3590 patients 
randomized to Placebo, Natalizumab, Dimethyl Fumarate, and Glatiramer Acetate. The 
outcome of interest was relapse or not relapse MS at two years. Table 1 presents the 
aggregated-level data of the trial arms as well as some baseline characteristics. We also had 
access to IPD from 1083 patients with relapsing-remitting MS, randomized to placebo arms 
included in nine clinical trials. The latter data was provided by the Clinical Path Institute 
(https://c-path.org/) and is also described in Table 1. We excluded variables with more than 
50% missing values. Between variables that were correlated (correlation coefficient larger 
than 70%) we retain those that were biologically plausible to be associated with the outcome 
based on the literature, their distribution and the amount of missing values. Finally, we 
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transformed some of the continuous variables to better approximate the normal distribution 
and merged categories with very low frequencies in categorical variables.  
2.2.2 Stage 1: Developing a baseline risk model for relapse at two years  
We first examined if the available sample size was enough for the development of a 
prognostic model (26). We calculated the events per variable (EPV) accounting for 
categorical variables and non-linear continuous variables (27). We also used the method by 
Riley at al. to calculate the efficient sample size for the development of a logistic regression 
model (28). We set Nagelkerke’s R2 = 0.15 (Cox-Snell’s adjusted R2 = 0.11) and the desired 
shrinkage equal to 0.9.  
We then fitted two main prognostic models. In the first model, we included predictors 
with non-zero coefficients in the least absolute shrinkage and selection operator (LASSO) 
(29).  We used the LASSO method both for the variable selection and for estimating the 
coefficients. We used 10 fold cross-validation to find the optimal penalty parameter that 
maximizes the area under the curve. The penalty parameter we chose is the one within one 
standard error of the minimum parameter, as previously recommended (6).  
The second prognostic model was based on previously identified prognostic factors.  
Pellegrini et al. analysed the annualized relapse rate MS in the DEFINE (training dataset) and 
CONFIRM (validation dataset) trials (30). They used different modelling approaches, 
including a fully additive model, ridge regression, LASSO, and elastic net regression. They 
selected the additive model including 14 prognostic factors based on its discrimination 
ability. We estimated the coefficients in each of these prognostic factors using penalized 
maximum likelihood estimation shrinkage method (31), (6). The optimal value of penalty was 
chosen as the one that maximizes a modified Akaike’s Information Criterion (6). Both 
models use common effects for the intercept and the regression coefficients (𝑏𝑏0𝑖𝑖 = 𝛽𝛽0, 𝑏𝑏𝑖𝑖𝑖𝑖 =
𝛽𝛽𝑖𝑖).  This decision was taken because all three trials are designed by the same company in a 
very similar way and any differences in the included populations shall be captured by 
including the baseline risk in the network meta-regression model, as described in the 
following section.  
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2.2.3 Stage 2: IPD Network meta-regression model for comparing four treatments in 
relapsing-remitting multiple sclerosis 
We assume that study-specific relative treatment effects do not have any residual 
heterogeneity beyond what is already captured by differences in baseline risk. Consequently, 
we employ a common effect IPD NMR model, both in the relative treatment effects 𝑑𝑑𝑖𝑖𝑏𝑏𝑗𝑗𝑖𝑖 and 
for the treatment effect modification of the risk score. Note that the between studies variance 
could not be estimated with only three studies (𝑑𝑑𝑖𝑖ℎ𝑗𝑗𝑖𝑖 = 𝐷𝐷ℎ𝑗𝑗𝑡𝑡= 𝛿𝛿𝑖𝑖 − 𝛿𝛿ℎ𝑗𝑗 ,   𝛿𝛿𝑟𝑟𝑟𝑟𝑟𝑟 =0, 𝑙𝑙𝑖𝑖ℎ𝑗𝑗𝑖𝑖 =
𝐺𝐺ℎ𝑗𝑗𝑡𝑡= 𝛾𝛾𝑖𝑖 − 𝛾𝛾ℎ𝑗𝑗,   𝛾𝛾𝑟𝑟𝑟𝑟𝑟𝑟 =0). We also assumed common coefficients for the risk score (𝑙𝑙0𝑖𝑖 =
𝛾𝛾0), as all three studies very similar in terms of design characteristics.  
To estimate the logit-probability (𝛼𝛼) of the outcome of a patient at the mean baseline 
population risk score, 𝐵𝐵𝐵𝐵𝑙𝑙𝑙𝑙𝑡𝑡(𝑅𝑅)�����������, under the overall reference treatment (i.e. Placebo), we used 
the external IPD Placebo-arm dataset. Then, we estimated the mean of 𝐵𝐵𝐵𝐵𝑙𝑙𝑖𝑖𝑡𝑡(𝑅𝑅𝑖𝑖𝑖𝑖) across all 
individuals and studies and we used this value as 𝐵𝐵𝐵𝐵𝑙𝑙𝑙𝑙𝑡𝑡(𝑅𝑅)�����������. 
2.2.4 Implementation and software 
All our analyses were done in R (32). We made the analysis code available in a GitHub 
library: https://github.com/htx-r/Reproduce-results-from-
papers/tree/master/ATwoStagePredictionModelMultipleSclerosis. 
For the development of the baseline risk model (2.2.2), we used the pmsampsize 
command to estimate if the available sample size was enough for the developed model.  The 
LASSO model was developed using cv.glmnet.  We first fitted the pre-specified model 
using the lrm command and used the pentrace command for the penalized maximum 
likelihood estimation. For the bootstrap internal validation, we used self-programming R-
routines.  
The IPD Network meta-regression model (2.2.3) was fitted in a Bayesian framework and 
we used programming routines in the R2Jags package (33). We set a normal distribution 
(𝑁𝑁(0,1/1000)) as prior distributions for all of the model parameters. We simulated two 
chains of 10,000 samples, we discarded the first 1,000 samples and we thinned for every 10 
samples. This was appropriate based on the visualization of the chain convergence. 
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3 Results 
3.1.1 Stage 1 Developing the baseline risk score 
A total of 57 candidate prognostic factors were available. After exclusion of variables 
with missing data and highly correlated with other variables, we ended up with 31 candidate 
prognostic factors (Appendix figure 1, Appendix figure 2). 
For the LASSO model, we used 2000 MS patients with complete data; 742 of whom 
relapsed in two years. The full model’s degrees of freedom were 45 and the EPV was 16.5. 
The recommended sample size for a newly developed model is 3456 patients, which is above 
the available sample size. For the pre-specified model, which does not involve selection of 
variables, the small number of degrees of freedom (14) led to a large EPV of 53 and a 
recommended minimum sample size 1076; which is well below the available sample size.  
Table 2 shows the two models, their coefficients and their performance with internal 
validation. Both models have almost the same discriminative ability, but the pre-specified 
model has a much better calibration slope.  
Both models predict almost the same mean risk for patients in our data (about 37%) as 
shown in Figure 1. The variation of the estimated baseline risk score is much higher using 
pre-specified model. Figure 1 also indicates that the baseline risk could be a prognostic factor 
for relapsing-remitting MS in two years, as the baseline risk score is higher for patients that 
did relapse than for patients that did not relapse, using both models, although the overlap is 
large, as shown also by the c-statistics in Table 2.  
3.1.2 Stage 2 Estimating heterogeneous treatment effects in an IPD network meta-
regression model 
Table 3 shows the estimated parameters from the network meta-regression model using 
the two different scores developed from the LASSO model and pre-specified model. Both 
models indicate the baseline risk as an important prognostic factor for relapsing at two years, 
as shown by the large values for 𝛾𝛾0. The estimates of log ORs for each treatment versus 
Placebo (𝛿𝛿𝑖𝑖)  are very similar with both models. However, they provide slightly different 
summary estimates for the coefficients of effect modification, i.e. 𝛾𝛾𝐷𝐷𝐷𝐷, 𝛾𝛾𝐺𝐺𝐺𝐺, 𝛾𝛾𝑁𝑁. Overall, none 
of the coefficients 𝛾𝛾𝐷𝐷𝐷𝐷, 𝛾𝛾𝐺𝐺𝐺𝐺,𝛾𝛾𝑁𝑁 is large.  
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Figure 2 shows the estimated predicted probabilities to relapse within two years 
depending on the estimated baseline risk, via LASSO and pre-specified risk models, under 
the four available treatment options - Appendix figure 3 presents the same results in OR 
scale. Both models give almost the same results for the treatment-effects estimation: 
Glatiramer Acetate seems to have the same performance as Dimethyl Fumarate in the 
observed range of baseline risk; Placebo results in the highest risk to relapse. Natalizumab is 
a drug initially considered less safe than the other two active options and associated with an 
increased mortality(34), (35), (33).  Table 4 shows the estimated predicted probabilities and 
the ORs of relapsing under all three available active treatments, using both models separately, 
for all patients, for low-risk patients (baseline risk<30%) and for high-risk patients (baseline 
risk>50%). The benefit of all three treatments, depends on the risk group. For high-risk 
patients (baseline risk>50%) the absolute benefit of Natalizumab compared to Dimethyl 
Fumarate is 15% for pre-specified model and 10% for the LASSO model. These correspond 
into 7 and 10 patients respectively that need be treated with Natalizumab to prevent one 
relapse. For low risk patients (baseline risk<30%), absolute benefit of Dimethyl Fumarate 
compared to Natalizumab is 3% for pre-specified model and 2% for the LASSO model.  The 
absolute differences between the treatments for all risk-groups are smaller using LASSO 
compared to the (penalized) pre-specified model. The predictions for the three drugs and 
Placebo for RRMS have been implemented in an interactive R-Shiny application available at 
https://cinema.ispm.unibe.ch/shinies/koms/.  
4 Discussion 
We developed a prediction model for heterogeneous treatment effects that combines risk 
modelling and network meta-analytical methods to make personalized predictions for an 
outcome of interest and to inform treatment decisions. We extended the idea of risk 
modelling approach (1) by combining network meta-analysis methods that allow comparing 
many treatment options via direct and indirect evidence (36). As the treatment options for 
each condition are numerous and most likely patient characteristics play an important role in 
the variability of treatment effects, this methodology could be an important tool for clinicians 
to make personalized decisions. Based on this model, we predicted the individualized 
probability to relapse within two years under each treatment. A crude network meta-analysis 
indicates that Natalizumab is the best treatment option on average. However, our model 
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showed that not all patients might benefit from Natalizumab, but only those at high risk of 
relapse.  
Given that a manageable number of characteristics is needed to establish the risk score, 
doctors and patients can enter these using our online tool 
(https://cinema.ispm.unibe.ch/shinies/koms/), estimate the risk to relapse in two years and see 
which of the three active treatments decreases the risk to relapse most. This tool shows the 
potential of the proposed approach, but may not yet be ready to be used in clinical practice. 
Decision-making tools need external validation with new patients, provide evidence about all 
available treatment options for many patient-relevant outcomes (e.g. long-term disability 
status), and also include issues of safety and cost. As few new trials might be available on 
existing drugs in the near future, observational data can be used to enhance the evidence.  
We used two different prognostic models to develop the risk score, which resulted in 
quite different predictions for the absolute treatment effects.  Our pre-specified model used 
variables previously identified as having an important prognostic ability. However, re-fitting 
the model to our data gave somewhat different results to those found by Pellegrini et al.  This 
is because Pellegrini et al. examined a different outcome (annualized relapse rate MS), used a 
negative binomial distribution to model it, and used different methodology to develop their 
model.  Additionally, variable selection approach via LASSO resulted into numerically 
different results to the pre-specified model, but their clinical interpretation, both in stage one 
and stage two were similar. Based on our results, which are conditional on our dataset, we 
would recommend that the pre-specified model rather than LASSO is considered for further 
development and evaluation. The pre-specified model was expected to be more stable 
because it did not involve a selection process. Hence, the available sample size was 
sufficient. The discrimination ability of the models was small but sufficient for our aim: risk 
models with low predictive ability (0.6 – 0.65) are often adequate to detect risk-based 
heterogeneous treatment effects (3). Considering the results of the pre-specified model, 
Natalizumab does not show benefit over Glatiramer Acetate and Dimethyl Fumarate in low 
risk patients (<30% risk of relapse). This information may be important to consider when 
selecting appropriate therapy for a given patient to achieve optimal benefit/risk.  
The applicability and usefulness of the application of our model in the relapsing-
remitting MS example is limited by several factors. First, the probability to relapse is not the 
only outcome that patients will consider when choosing a treatment;  long-term disability 
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status would also determine their choice (37). Unfortunately, long-term outcomes are not 
available from RCTs. Consequently, the investigators who want to use this framework would 
need to establish the predictive ability of the short-term outcomes reported in RCTs to the 
long-term outcomes that matter to patients (typically available only in registries and 
observational programs). Unfortunately, we did not have access to such data, which would 
have also allowed us to validate externally the model. That can be a further line of future 
research. Finally, patients and doctors would most probably make decisions after considering 
several beneficial and adverse events as well as treatment characteristics and include more 
alternative treatment options. We illustrated our model using the drugs tested in the RCTs 
that we had access to and consequently included only three active drugs out of a dozen 
possible choices. However, our framework is flexible enough and can be applied to as many 
outcomes and treatments as required. Then, the absolute effects of treatments could be 
synthesized across outcomes. In terms of further developments and to extend the application 
of the method, given that IPD from the entire network may not be always available, it would 
be valuable to extend the methods proposed here to situations where the evidence base is a 
mixture of IPD and AD.  
Several limitations of the general approach need to be mentioned. First, our framework 
requires at least one IPD dataset for each included intervention in order to estimate all model 
parameters. Acquiring IPD data is not easy and several papers have documented the 
difficulties encountered in the process. When reducing all patient information into the risk 
score, we make the assumption that the set of selected variables captures adequately both 
prognosis and effect modification; in other words that all prognostic factors are also effect 
modifiers and vice versa. This is not necessarily the case as the variables that impact on 
prognosis might be different to those that modify the relative treatment effects. This 
assumption is difficult to evaluate, unless the outcome is well studied and many prognostic 
studies exist on the topic. Finally, in the present paper, the model to develop the risk score 
(the first stage) has been validated only internally while the predictive accuracy of our two-
step framework has not been validated at all. In future work, its performance needs to be 
validated using not only the classical metrics such as discrimination and calibration, but also 
metrics related to the absolute benefit (33). To those limitations, one should add the standard 
challenges encountered in prognostic modelling. Some prognostic factors may not be 
available in one or more studies and multiple imputation methods, may be needed to address 
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this problem (38). Finally, numerous candidate prognostic factors might render the available  
sample size insufficient and model selection challenging (6). 
The approach offers many methodological advantages and opportunities for further 
development. Model selection approaches and methods to shrink coefficients to avoid 
extreme predictions are not available in the meta-analysis context. Our proposal to use the 
risk score as the only covariate in network meta-regression shifts the variable selection 
problem into the logistic regression model for which penalization methods are well 
established. Measuring treatment effects ideally relies on RCT evidence, and we had access 
to IPD data from 3 trials. Network meta-regression models can also include aggregated data 
from published studies, so our approach can be extended provided that mean values of 
important patients’ characteristics are also reported in the published papers. That will 
considerably improve the power of the model. In this study, we used only RCTs, but 
observational data, from registers and cohorts can also be integrated in various stages: to 
develop the risk score, to calibrate or update the risk score model, to externally validate the 
model, to inform the baseline effects, or even the relative treatment effects and their 
interactions with the score using appropriate bias-adjusted modelling. Methods to include 
single arm trials in network meta-analysis are also available and could be incorporated to 
further extend the model. Finally, the flexibility of our model, fitted within a Bayesian 
framework, allows taking into account expert opinion about the importance of the included 
variables or the credibility of the observational evidence. The major advantage of our 
approach is that, if applied to all health outcomes of interest, it has the potential to inform 
patients and their doctors, but also other stakeholders, including manufacturers and HTA 
agencies, about the treatment that is most appropriate for each one of patients and hence 
contribute to the major aim of the clinical society, this of personalized medicine.  
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Table 1 Baseline characteristics of Multiple Sclerosis patients enrolled in the trials 
Study Treatment  Number of 
randomized 
patients  
Number of 
patients with 
relapse of MS 
in two years  
 Age  
 
 
 
 
 
Sex 
 
 
 
 
 
Baseline 
EDSS 
 
 
 
 
Number of 
relapses in 
previous  
year  
 
 
    Mean 
(sd) 
Female  
N  
(%) 
Male  
N  
(%) 
 
Mean 
(SD) 
Median 
(min, max) 
AFFIRM  
 
Natalizumab 
 
Placebo 
939 
 
627 
 
312 
359 (38.2%) 
 
183 (29.2%) 
 
176 (56.4%) 
36.0 
(8.3) 
657 
(70.0) 
282 
(30.0) 
 
2.3 
(1.2) 
1  
(0, 12) 
CONFIRM  
 
Dimethyl Fumarate 
 
Glatiramer Acetate 
 
Placebo 
1417 
 
703 
 
351 
 
363 
451 (31.8%) 
 
185 (26.3%) 
 
117 (33.3%) 
 
149 (41.0%) 
 
37.3 
(9.3) 
993 
(70.1) 
424 
(29.9) 
 
2.6 
(1.2) 
1  
(0, 8) 
DEFINE  
 
Dimethyl Fumarate 
 
Placebo 
1234 
 
826 
 
408 
394 (31.9%) 
 
212 (25.7%) 
 
182 (44.6%) 
38.5 
(9.0) 
908 
(73.6) 
326 
(26.4) 
 
2.4 
(1.2) 
1  
(0, 6) 
 
Placebo arms 
dataset 
 
Placebo 
 
1083 
 
801 (74.0%) 
 
41.19 
(10.3) 
 
752 
(69.4) 
331 
(30.6) 
 
 
NA 
 
NA 
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Table 2 Estimated LASSO shrunk coefficients and coefficients from the pre-specified model together with 
penalized maximum likelihood estimation. The discrimination (C-score) and the calibration slopes are 
also shown. 
Variables LASSO model Coefficients 
Pre-specified model 
Coefficients (S.E.) 
C-score 0.60 0.62 
Calibration slope 1.54 1.05 
 Intercept -0.4424 -0.8656 (0.866) 
Age -0.0013 -0.0181 (0.005) 
Sex (male vs female) - -0.1379 (0.092) 
Baseline weight -0.0002 - 
Baseline EDSS 0.0963 0.1683 (0.047) 
Years Since Onset of Symptoms - 0.0587 (0.063) 
Ethnicity (white vs other) - -0.0142 (0.117) 
No. of relapses 1 year prior to study 0.2971 0.5963 (0.170) 
Months since pre-study relapse - -0.0126 (0.009) 
Prior MS treatment group (yes vs no) 0.0241 0.1901 (0.085) 
Region (India vs Eastern Europe) 0.0000 - 
Region (North America vs Eastern Europe) 0.0000 - 
Region (Rest of world vs Eastern Europe) 0.0000 - 
Region (Western Europe vs Eastern Europe) 0.2374 - 
Timed 25-Foot Walk - -0.1718 (0.158) 
9-Hole Peg Test - 0.3011 (0.208) 
PASAT-3 - 0.0029 (0.004) 
VFT 2.5% - -0.0010 (0.004) 
Baseline Gadolinium volume 0.0001 - 
Baseline SF-36 PCS -0.0120 -0.0195 (0.005) 
Baseline SF-36 MCS - 
 
0.036 (0.004) 
Baseline Actual Distance Walked  
(>500 vs <=500) -0.0746 - 
S.E: Standard Error; EDSS: Expanded Disability Status Scale; MS: multiple sclerosis; PASAT: Paced Auditory Serial Addition Test; VFT: 
Visual Function Test; SF-36 PCS: Short Form-36 Physical Component Summary; SF-36 MCS: Short Form-36 Mental Component 
Summary 
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Table 3 Estimated parameters from the network meta-regression model using the two different scores 
developed from the LASSO model and pre-specified model 
Estimated parameters from IPD 
NMR model 
LASSO model 
Mean (95% Cr. Interval) 
Pre-specified model 
Mean (95% Cr. Interval) 
γ0 2.30 (1.78, 2.8) 1.26 (0.95, 1.58) 
𝜹𝜹𝑫𝑫𝑫𝑫 -0.92 (-1.20, -0.64) -0.89 (-1.18, -0.60) 
𝜹𝜹𝑮𝑮𝑮𝑮 -0.72 (-1.15, -0.28) -0.71 (-1.15, -0.26) 
𝜹𝜹𝑵𝑵 -1.24 (-1.55, -0.93) -1.22 (-1.53, -0.93) 
𝜸𝜸𝑫𝑫𝑫𝑫 0.90 (-0.20, 1.98) 0.25 (-0.35, 0.87) 
𝜸𝜸𝑮𝑮𝑮𝑮 0.64 (-1.02, 2.39) 0.23 (-0.71, 1.3) 
𝜸𝜸𝑵𝑵 -0.02 (-1.16, 1.07) -0.26 (-1.01, 0.43) 
𝒆𝒆𝛄𝛄𝛄𝛄: OR of relapse in two years for one unit increase in logit-risk in untreated patients (placebo) 
𝒆𝒆𝜹𝜹𝑫𝑫𝑫𝑫: OR of relapse under Dimethyl Fumarate versus Placebo at the study mean risk 
𝒆𝒆𝜹𝜹𝑮𝑮𝑮𝑮: OR of relapse under Glatiramer Acetate versus Placebo at the study mean risk 
𝒆𝒆𝜹𝜹𝑵𝑵: OR of relapse under Natalizumab versus Placebo at the study mean risk 
𝒆𝒆𝜸𝜸𝑫𝑫𝑫𝑫: OR of relapse under Dimethyl Fumarate versus placebo for one unit of increase in the logit risk 
𝒆𝒆𝜸𝜸𝑮𝑮𝑮𝑮: OR of relapse under Glatiramer Acetate versus placebo for one unit of increase in the logit risk 
𝒆𝒆𝜸𝜸𝑵𝑵: OR of relapse under Natalizumab versus placebo for one unit of increase in the logit risk 
DF: Dimethyl fumarate; GA: Glatiramer acetate; N: Natalizumab 
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Table 4 Predicted % probabilities and ORs (relative benefits) of relapse in two years, using baseline risk 
scores developed with the LASSO and pre-specified models. Results are shown for all patients, for low-
risk patients (baseline risk<30%) and for high-risk patients (baseline risk>50%) in the observed range of 
baseline risk. The cut-offs have been chosen arbitrarily for illustrative purposes. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Benefits Model Treatment All 
patients  
Baseline Risk 
<30% 
Low-risk patients 
Baseline Risk 
>50% 
High-risk 
patients 
  Dimethyl Fumarate 62% 18% 93% 
 LASSO Glatiramer Acetate 64% 23% 93% 
Absolute 
Benefits 
(%) 
 Natalizumab 54% 20% 82% 
  Dimethyl Fumarate 53% 20% 84% 
 Pre-specified  Glatiramer Acetate 56% 23% 86% 
  Natalizumab 
 
46% 23% 69% 
  Dimethyl Fumarate vs 
Placebo 
0.52 0.25 0.81 
 LASSO Glatiramer Acetate  vs 
Placebo 
0.57 0.35 0.81 
Relative  
Benefits 
(OR) 
 Natalizumab  vs 
Placebo 
0.29 0.29 0.28 
  Dimethyl Fumarate  vs 
Placebo 
0.42 0.31 0.53 
 Pre-specified  Glatiramer Acetate  vs 
Placebo 
0.50 0.38 0.63 
  Natalizumab  vs 
Placebo 
0.31 0.40 0.23 
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Figure 1 The distribution of baseline risk for LASSO model (A) and pre-specified model (B) for patients 
that did not relapse MS in two years (RELAPSE2year=0) and for patients that did relapse MS in two 
years (RELAPSE2year=1). The dotted lines indicate group means and the solid line the overall mean risk 
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Figure 2 Predicted probability to relapse in two years as a function of the baseline risk estimated with 
LASSO (A) or pre-specified model (B). The x-axis shows the baseline risk score of relapsing in two years. 
Between the two dashed vertical lines are the baseline risk values observed in our data 
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Appendix 
Appendix figure 1 Flow-chart for the number of candidate prognostic factors 
 
Appendix figure 2 Venn diagram for candidate characteristics to include in the prognostic model (stage 
1). Light blue indicates all 31 characteristics after deleting the correlated variables and those with a big 
amount of missing values (>50%). Light green indicates the variables selected by LASSO and purple 
indicates the variables included in pre-specified model 
 
FSS: Functional System Score; VAS: Visual Analog Scale; EDSS: Expanded Disability Status Scale; SF-36 PCS: Short Form-36 Physical 
Component Summary; SF-36 MCS: Short Form-36 Mental Component Summary; VFT: Visual Function Test. 
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Appendix figure 3 ORs of relapse in two years as a function of the baseline risk estimated with LASSO 
(A) or pre-specified model (B). The x-axis shows the baseline risk score of relapsing in two years. Between 
the two dashed vertical lines are the baseline risk values observed in our data 
 
 
 
 
 
